GlassScriptPhysician profile
Carlos E De Cabrera
NPI 1952884637
$1,620.31
in general payments reported to CMS, 2019-2025
14 companies · $512 in 2025
The $512 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $225 · 2022: $715 · 2023: $60.92 · 2024: $107 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $638 · Education: $42.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $637.91 |
| Education | $42.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| One Lambda, INC. | $383.59 | 2025 | |
| Amgen INC. | $352.24 | 2021-2024 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $222.42 | 2022 | |
| Vifor Pharma, INC. | $182.11 | 2022-2025 | Veltassa |
| Aurinia Pharma U.S., INC. | $122.74 | 2022 | |
| Opko Pharmaceuticals, LLC | $82.10 | 2022-2023 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $65.23 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.67 | 2022 | |
| Fresenius USA Marketing, INC. | $43.79 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $41.16 | 2022 | |
| Impel Pharmaceuticals INC. | $22.85 | 2022 | |
| Lilly USA, LLC | $20.28 | 2022 | |
| Calliditas Therapeutics US INC. | $18.88 | 2023 | Tarpeyo |
| Biohaven Pharmaceutical Holding Company LTD. | $15.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos De Cabrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.